首页 › 期刊 › 医学 › Annals of Hepato-Biliary-Pancreatic Surgery
Annals of Hepato-Biliary-Pancreatic Surgery
出版商:The Korean Association of Hepato-Biliary-Pancreatic Surgery · ISSN:2508-5778, 2508-5859 · 国家/地区:KR · 类型:journal · OA 开放获取 · 官网:http://www.jhbps.org
研究主题:Pancreatic and Hepatic Oncology Research · Cholangiocarcinoma and Gallbladder Cancer Studies · Gallbladder and Bile Duct Disorders · Hepatocellular Carcinoma Treatment and Prognosis · Organ Transplantation Techniques and Outcomes
数据覆盖:8 个公开学术数据源交叉核验(crossref、fqb、jcr、openalex、scimago、wikidata、xr、cwts)。
数据来源与实体核验
期刊官网 · OpenAlex 期刊实体 · Wikidata 期刊实体
核心指标
- 影响因子(JCR 2025):1.800
- JCR 分区:Q2(SURGERY)
- 中科院分区(2025):医学 4区,大类排名 4083/5603;小类:GASTROENTEROLOGY & HEPATOLOGY 胃肠肝病学 4区,排名 113/143
- 新锐分区(2026):医学 4区
- SJR:0.613(Q2),2025 年,South Korea
- CWTS 2025:SNIP 0.915 · IPP 1.688 · 自引率 5.9%
- h-index:27
- i10 指数:157
- 近两年篇均被引:1.64
- 载文量 1961 · 总被引 4875
- Crossref DOI 总量:1895,近期 161
逐年趋势
- 近年影响因子:2023 1.1 → 2024 1.7
- 近年 SJR:2022 0.148(Q3) → 2023 0.212(Q3) → 2024 0.343(Q3) → 2025 0.613(Q2)
同学科期刊推荐
- CA-A CANCER JOURNAL FOR CLINICIANS — IF 685.2 · JCR Q1 · 中科院1区(Top)
- The Lancet — IF 109.0 · JCR Q1 · 中科院1区(Top)
- MMWR Surveillance Summaries — IF 96.9 · JCR Q1 · 中科院1区(Top)
- Nature Reviews Clinical Oncology — IF 94.6 · JCR Q1 · 中科院1区(Top)
- Nature Reviews Drug Discovery — IF 91.2 · JCR Q1 · 中科院1区(Top)
- New England Journal of Medicine — IF 84.5 · JCR Q1 · 中科院1区(Top)
- Signal Transduction and Targeted Therapy — IF 81.2 · JCR Q1 · 中科院1区(Top)
- Annals of Oncology — IF 80.4 · JCR Q1 · 中科院1区(Top)
常见问题
《Annals of Hepato-Biliary-Pancreatic Surgery》的影响因子是多少?
根据 JCR 2025 年数据,《Annals of Hepato-Biliary-Pancreatic Surgery》的最新影响因子(IF)为 1.800。
《Annals of Hepato-Biliary-Pancreatic Surgery》是几区期刊?
《Annals of Hepato-Biliary-Pancreatic Surgery》中科院分区(2025年版)为医学4区,JCR 分区为 Q2。
《Annals of Hepato-Biliary-Pancreatic Surgery》是开放获取(OA)期刊吗?
是,《Annals of Hepato-Biliary-Pancreatic Surgery》是开放获取(Open Access)期刊。
本刊近期代表论文
- Deep learning-based surgical phase recognition in laparoscopic cholecystectomy (2024 · 被引 12)
- Survival benefit of neoadjuvant FOLFIRINOX for patients with borderline resectable pancreatic cancer (2024 · 被引 7)
- Comparative accuracy of four guidelines to predict high-grade dysplasia or malignancy in surgically resected pancreatic intraductal papillary mucinous neoplasms: Small nuances between guidelines lead to vastly different results (2024 · 被引 7)
- Clinical features of recurrence after hepatic resection for early-stage hepatocellular carcinoma and long-term survival outcomes of patients with recurrence: A multi-institutional analysis (2022 · 被引 14)